Sanofi S.A. - SNY EV/Sales Multiple

Public company logo of sanofi.com (SNY)

Sanofi relies on Dupixent sales while facing pressure from EU regulators and the risk of generics. The current valuation of the company relative to revenue on GURU.Markets includes the 2429.20 indicator, which determines the metric's magnitude. Vaccines and over-the-counter products provide stability, while the high margins of the flagship drug effectively offset the costs of restructuring the R&D portfolio.

SNY: Sanofi S.A. Enterprise Value-to-Revenue Ratio 11/23/2025 - 11/20/2026

Sanofi Group - analytical breakdowns and key metrics (SNY)

- market price and analyst price targets:
Initial company analysis:SNY (sanofi.com)
Brand item of Sanofi Aventis

Given the capital intensity of R&D and stringent regulatory oversight in pharmaceuticals, the EV/Sales history for Sanofi reflects the enterprise value of the business relative to its annual revenue. This metric measures the efficiency of revenue monetization by stripping the valuation of the impact of debt load. It is critical for investors to monitor the line's deviation from average values to avoid purchasing an overvalued asset before it reverts to its fundamental mean.